Deupirfenidone compared with pirfenidone and placebo in idiopathic pulmonary fibrosis (ELEVATE-IPF): a phase 2b randomized placebo-controlled trial
Year: 2026
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: RATIONALE: Deupirfenidone is a strategically deuterated form of pirfenidone that retains pharmacodynamic activity but has a differentiated pharmacokinetic profile that may enable improved efficacy and favorable tolerability in patients with idiopathic pulmonary fibrosis (IPF). OBJECTIVES: To evaluate the efficacy and safety of deupirfenidone compared with placebo and pirfenidone in patients with IPF. METHODS: Patients were randomized 1:1:1:1 to deupirfenidone 550 mg TID, deupirfenidone 825 mg TID, pirfenidone 801 mg TID, or placebo. The primary endpoint was the rate of change in forced vital capacity (FVC) for the combined arms of deupirfenidone versus placebo at 26 weeks. The primary and secondary analyses used Bayesian and frequentist approaches, respectively. MEASUREMENTS AND MAIN RESULTS: A total of 257 patients with IPF were randomized, and the proportion on treatment at the end of the study was 80.0%, 68.3%, 64.6%, and 78.1% for the placebo, pirfenidone, deupirfenidone 550 mg, and deupirfenidone 825 mg arms, respectively. Posterior mean change in FVC for placebo was -110.71 mL (95% credible interval (CI), -148.75, -70.98), and for the combined deupirfenidone arms was -48.42 mL (95% CI, -87.66, -9.04) with a posterior mean difference of 62.29 mL (95% CI l, -6.13, 115.73; posterior probability, 0.985). Using a frequentist approach, the adjusted mean change in FVC for the placebo arm was -112.5 mL (95% CI, -167.2, -57.8), and for the deupirfenidone 825 mg arm was -21.5 mL (95% CI, -78.2, 35.1); the adjusted mean difference was 91.0 mL (95% CI, 12.2, 169.7; P = .02). The most common adverse events for each active treatment arm were gastrointestinal. CONCLUSIONS: In patients with IPF, treatment with deupirfenidone slowed lung disease progression over 26 weeks. TRIAL REGISTRATION: Clinicaltrials.gov number NCT05321420.
Authors: Toby M Maher, Mark J Hamblin, Won-Il Choi, Amy Hajari Case, Ioannis P Tomos, Argyrios E Tzouvelekis, Jessica E Shore, Miguel A Bergna, David Golod, Eric Elenko, Yanqiong Zhang, Camilla S Graham, Jin Woo Song, Tejaswini Kulkarni, and the ELEVATE IPF Investigators, Martin Maillo, Miguel Bergna, Ramon A Rojas, Luis Wehbe, Alexis Cazaux, Alejandro Chirino, Pedro Carlos Elias, Luciana Molinari, Alicia Molina, Cristian Fazio, Victoria Kohn, German Arce, Ernesto Raso, Matias Florenzano, Georgina Miranda, Juana Pavie Gallegos, Absalon Rafael Silva Orellana, Diana Cano, Tatiana Valencia Castano, David Tchkonia, Kakha Vacharadze, Vakhtang Katsarava, Nani Gonjilashvili, Lali Kupreishvili, Katerina Antoniou, Aikaterini Manika, Argyrios Tzouvelekis, Ioannis Tomos, Efrosyni Manali, Jaydip Deb, Sandeep Katiyar, Anjali R Nath, Hafiz Deshmukh, Tejas Kakkad, Rajesh Swarnakar, Gururaj Udachankar, Asish Deshmukh, Syazatul Syakirin Sirol Aflah, Yong-Kek Pang, Noorul Afidza Muhammad, Megat Razeem Abdul Razak, Irfhan Ali Hyder Ali, Chan Tha A Hing, Andrea Colli, Juan Francisco Moreno, Francisco Sanchez Llamas, Rodolfo Posadas Valay, Carlos Herrera Garcia, Joel Santiaguel, Mae Campomanes, Pamela Joy Dionisio, Cristian Oancea, Lavinia Davidescu, Cristian Cojocaru, Riaz Suleman Dawood, Ismail Kalla, Larry Mey, Michael Van Der Linden, Paul Graham Williams, Jin Woo Song, Yong Hyun Kim, Hyoung Kyu Yoon, Eun Kyung Kim, Hye Sook Choi, Sun Hyo Park, Hongseok Yoo, Won-Il Choi, Yongchul Lee, Yangjin Jegal, Sung Hwan Jeong, Hong-Joon Shin, DongWon Park, Jae Ha Lee, Joo Hun Park, Kittima Bangpattanasiri, Pailin Ratanawatkul, Krittika Teerapuncharoen, Thomas P Jensen, Barbara Wendelberger, Farah Khandwala, Anna McGlothlin, Aaron Milstone, Abhishek Singla, Juan Fernandez, Mark Hamblin, Tejaswini Kulkarni, Rafael Lupercio, Benjamin Bregman, Richard Parisi, Yolanda Mageto, Damien Patel, Toby Maher, William Stringer, Ather Siddiqi, Shilpa Johri, Gerard Criner, Bruce Rankin, Ramana Puppala, Amy Case, Ryan Klein, Murali Ramaswamy, Lisa Lancaster, Todd Astor, Ameer Rasheed
Institutions: University of Southern California, Imperial College London, The University of Kansas Health System, University of Kansas Medical Center, Myongji Hospital, Hanyang University, Piedmont Atlanta Hospital, Piedmont HealthCare, University of Patras, Pulmonary Fibrosis Foundation, PureTech (United States), Asan Medical Center, University of Ulsan, University of Alabama at Birmingham
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Keywords: pirfenidone, idiopathic pulmonary fibrosis, deuterated drugs, forced vital capacity, lung function decline, antifibrotic therapy, pharmacokinetics, drug safety, treatment tolerability, Bayesian analysis, frequentist analysis, dose comparison, medication adherence, treatment discontinuation
Open Access status: hybrid
Funder: PureTech Health
OpenAlex ID: W7148454282
